Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

ICON8 was an international, multicentre, randomised, phase 3 trial done across 117 hospitals in the UK, Australia, New Zealand, Mexico, South Korea, and Ireland. Median follow-up was 29.5 months for the neoadjuvant chemotherapy followed by DPS population. Median progression-free survival was 14.4 months for patients with a RECIST. complete or partial response.

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Bevacizumab is approved in combination with chemotherapy for the treatment of ovarian cancer. We enrolled women who had previously received first-line platinum-based therapy including bevacizomab. Median progression-free survival was 8.8 months.

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial

We did a randomised, open-label, phase 3 trial at 17 cancer centres in France. Eligible patients were aged 18–70 years and had colorectal cancer with peritoneal metastases. Median overall survival was 41.7 months in the cytoreductive surgery plus HIPEC group.

Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials

Two radiotherapy fractionation schedules are used to treat locally advanced bladder cancer. 55 Gy in 20 fractions is non-inferior to 64 Gy in 32 fractions with regard to both invasive locoregional control and toxicity. 55 Gy should be adopted as a standard of care for bladder preservation in bladder cancer patients.

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial

Ultra-hypofractionation was non-inferior to conventional fractionation regarding 5-year failure-free survival and toxicity. The HYPO-RT-PC trial was done in 12 centres in Sweden and Denmark. In seven of ten bowel symptoms or problems the proportion of patients with clinically relevant deteriorations at the end of radiotherapy was significantly higher in the ultra-hyp fractionation group.

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

German Hodgkin Study Group HD17 trial investigated whether radiotherapy could be omitted without loss of efficacy in patients with early-stage unfavourable Hodgkin lymphomas. 5-year progression-free survival was 97% in the standard combined-modality treatment group and 95% in PET4-guided treatment group.

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

PALLAS is an ongoing multicentre, open-label, randomized, phase 3 study that enrolled patients at 406 cancer centers in 21 countries. 3-year invasive disease-free survival was 88.2% (95% CI 85 2–90 6) for palbociclib plus. endocrine therapy.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC) The most common grade 3–4 treatment-related adverse events were neutropenia, anaemia, diarrhoea, and increased lipase. The most common grade 3–4 treatment-related adverse events were neutropenia, anaemia, diarrhoea, and increased lipase. The risk-benefit profile of this regimen is considered favourable.

Departments

Recent Posts